Kinarus Therapeutics Holding AG

Investor Presentation • Sep 18, 2025

20 Years of Experience and Growing Fast

Investor Presentation September 2025

• The company was founded in 2002
• Solid portfolio with 40 products in distribution, recently contracted 4 new products with Phoenix Labs
• Several products in development pipeline with C-PTBE-01 (peritumoral brain edema) as late stage lead product candidate, Phase 3 ready
• Haemopressin (Terlipressin) was developed as a pharmaceutical product, launched internationally and sold to a European pharmaceutical company
• Experienced management with significant stake in company (founder controlled)
• Curatis Holding AG has been listed on SIX since April 2024 (SIX:CURN)

Vision: We are a leading provider of specialist medicines in Europe and beyond

We search for innovative medicines for the prevention, diagnosis and treatment of rare diseases and other niche areas. We commercialize and bring products to market.

Distribution of specialist medicines

Current market

Expansion

Growing and profitable distribution business Switzerland

• Curatis sales business currently focused on Switzerland

• 40 products distributed in Switzerland

• Sales growth H1 2025: 14%
• Estimated revenues in 2025: >10m CHF
• Announced distribution contract with Phoenix Labs for 4 new products
• Several others under review

Expansion of distribution

• Expansion of rare disease and specialty medicines knowledge into the following countries is planned:
  • Germany
  • France
  • Italy
  • United Kingdom

	Indication	Project	Clinical development
			I	IIa	IIb	MA Pivotal Phase III
y t t c ri e o oj ri r P P	Peritumoral brain edema secondary to malignant brain tumors	C-PTBE-01 (corticorelin)				Pivotal study
	Migraine with aura	C-AM-01
	Medication overuse headache	C-MOH-01				d ol h
	Search for inflammatory or fibrotic Orphan or Ultra orphan diseases	KIN001				n O

PTBE secondary to brain cancer

Brain Cancer

Metastatic Primary

• Is the most prevalent type of brain cancer in adults
• Major impact on patient's quality of life
• Estimates of up to 400.000 prevalent patients in US alone ¹
• Most common primary sites are 1,2:
  • pulmonary (39–56%)
  • breast (13–30%)
  • skin (8–11%)
  • gastrointestinal (6–9%)
  • renal cancer (2–6%)
• Overall survival generally exceeds 6 months, with a range of 8-16 months ³
• Association with PTBE in most cases ⁴
• Brain metastases in children are extremely rare, but can be seen secondary to neuroblastoma

• High mortality despite often early diagnosis
• Major impact on patient's quality of life
• In the US alone ~180.000 prevalent patients reported for 2022 ⁵
• Association with PTBE of up to 60% of cases dependent on the subtype of brain cancer
• Most common adult primary brain tumors are ⁶ :
  • glioblastoma (49%)
  • other gliomas with CNS parenchyma infiltration (30%)
  • primary CNS lymphoma (7%)
• Most common pediatric primary brain tumors are ⁷ :

page 7

• Medulloblastoma (20%)
• high-grade gliomas (15%)
• Ependymoma (10%)

Metastatic Brain Cancer

Cancer Origin	US Prevalence 1	US Prevalence Presenting with Brain metastases 2
Lung	635,547	101,688
Melanoma	1,504,676	22,570
Breast	4,091,181	12,274
Colorectal	1,416,499	4,249

Definition

PTBE is associated with many primary and metastatic brain tumours, which through the accumulation of extracellular fluid around the tumour results in compression of brain tissue and subsequent impairment of brain function(s)

Impact

PTBE significantly compounds the morbidity of brain tumors, causing headaches, seizures, cognitive impairment, and potentially life-threatening increased intracranial pressure.

PTBE represents a critical challenge in neuro-oncology, as it both exacerbates tumor symptoms and limits treatment options. Managing this condition effectively without harmful side effects could transform patient outcomes and quality of life.

PTBE secondary to metastatic brain tumor

Lung, Melanoma, Breast, Colorectal, Kidney ~100,000

PTBE secondary to primary brain tumor

Gliomas ~90,000

• The standard treatment for PTBE are corticosteroids, developed first in 1948 ¹ , which often cause significant side effects
  • such as severe myopathy, muscle wasting, impaired glucose metabolism, immunosuppression, glucose intolerance, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes
• Corticosteroids can also hamper the effect of certain cancer therapies such as chemotherapy or modern immunotherapies
• There are no other approved pharmacologic PTBE treatments, and more tolerable alternatives are highly needed
  • Bevacizumab is used off-label based on Phase 2 efficacy data, but is also known to have severe side-effects

As overall survival in malignant brain tumors continues to improve due to earlier detection and innovative treatments, there is a critical and growing need for PTBE treatments with significantly more tolerable safety profiles

C-PTBE-01

Corticorelin

High unmet medical need

▪ Medicine to treat PTBE effectively without the severe, systemic side effects of corticosteroids that does not impair underlying chemo- or modern immunotherapies in adult or pediatric cancer patients with PTBE secondary to malignant brain tumors

Goal of therapy:

• Completely replace or significantly reduce corticosteroid use in patients with PTBE
• Significantly improved tolerability resulting in improved quality of life
• Avoid impairment of certain chemotherapies or modern immunotherapies potentially enhancing their efficacy

Lead Project C-PTBE-01: Characteristics and benefits of corticorelin

• The active substance of C-PTBE-01 is Corticorelin (hCRF), an endogenous neuropeptide of of 41 amino acids sequence
• Corticorelin can positively impact the in PTBE disrupted blood-brain barrier. In preclinical studies it showed an antiangiogenetic and anti-VGEF effect and anti-tumor effect.
• Corticorelin has shown a strong steroid-sparing effect in both preclinical and importantly in two clinical safety and efficacy studies, demonstrating the potential for a significant reduction or complete replacement of steroid use. This in turn may reduce or avoid the severe glucocorticoid-related side effects and thus improve the quality of life of patients.
• By being able to lower the dose or replace corticosteroids completely, there is also the potential to maintain the efficacy of novel tumor therapies for PTBE patients currently treated with corticosteroids.
• C-PTBE-01 is classified as biologic in the USA. Curatis will submit a biologics license application which benefits from 12 years of market exclusivity.

Corticorelin Key Clinical Data in PTBE Highlights Potential

A completed phase 3 clinicaltrial & open label extension evaluated corticorelin in PTBE in patients with malignant brain tumors which demonstrated:

one month ¹ 40%clinically meaningful difference in sub analysis of primary endpoint in patients with PTBE secondary to brain metastases (70.0% vs 30.4% p<0.01) ²

In addition, corticorelin acetate:

• Was well tolerated and highly safe with AEs of note: infusion site reactions and flushing 1, 2
• Demonstrated consistent and dose-dependent neurological improvement. ¹
• The reduction in steroid requirement for patients with PTBE was associated with a reduction in the incidence and severity of common steroid adverse effects. ²

▪ Significant Market Opportunity

• More than 150,000 patients are affected by peritumoral brain edema in the USA
• Globally around 500,000 patients may suffer from peritumoral brain edema
• Estimated peak sales: >1 billion USD

▪ Strong IP & Exclusivity Protection

• Biologics License Application: 12 years of market exclusivity in the USA
• Data Protection: 10 yrs. in Europe, 8 yrs. in Japan
• Orphan Drug Status: USA 7 years, EU 10 years, Japan 10 years; efforts ongoing

• Proceeding without delay to a regulatory submission for a pivotal Phase 3 study
• Adaptive trial design with dose optimization lead-in phase, followed by confirmatory segment
• Partnering process for C-PTBE-01 initiated in Q3 2025 (focus on Global Leaders in Oncology and Specialty Care)
• Next Step: Preparation of a pivotal Phase 3 study

▪ Potential Expansion Indications

• Primary brain tumors in children and adults
• Potentiation of anti-VGEF tumor therapies
• Anti-tumor therapy and/or potentiation thereof

C-AM-01

▪ Description ofthe disease

• There are 2 types of migraine: migraine with aura (20%) and migraine without aura (80%)
• An aura is a temporary visual disturbance such as flashes of light, flickering, zigzag lines or blind spots, tingling or numbness in the hands, arms or face, speech disorders, dizziness, partial paralysis. These symptoms, sometimes similar to signs of a stroke, can be debilitating and frightening to patients
• Migraine with aura can have a massive impact on patients' lives
• There is currently no specific preventive treatment → large unmet medical need
• C-AM-01 is an oral platelet aggregation inhibitor
• Two phase IIa clinical proof-of-concept studies indicate a reduction in the number of attacks
• Peak sales potential: approx. US\$ 500m
  • Migraine prevalence is approx. 15-20% of the total population; approx. 15-30% of migraine patients experience aura symptoms
  • Curatis focuses on serious cases

▪ IP/ patent protection

• USA: Use and dosage regimen patent granted in Nov. 2021
• EU: 10 yrs. data protection
• Japan: 8 yrs. data protection

Next step:

▪ Partnering readiness and partner search

Team

Board of Directors and Management

Executive Management

Patrick Ramsauer

• CFO
• Formerly UBS (M&A and Corporate Finance) and Partner at YUMA Capital

Advisory Board

Advisory Board

Stewart Goldman, MD

• Internationally renowned pediatric oncologist, Chair of the Department of Child Health at the University of Arizona College of Medicine, Phoenix, Arizona, Senior Vice President of Research at Phoenix Children's' and Sybil B Harrington Endowed Chair of Oncology
• Accomplished leader in brain tumor research, with significant contributions to the medical and scientific communities
• Published more than 170 peer-reviewed articles

Dr. Anthony Man, B.Med Sci, MB, BS, FRCP (UK)

• Physician specialized in internal medicine and oncology
• Experience in international clinical research and drug development through all clinical stages of new drug development from Investigational New Drug to Life Cycle Management in multiple therapeutic areas including oncology, infectious disease, rheumatology, metabolic disease, respiratory, cardiovascular, ophthalmology and transplantation medicine
• Lederle, Roche, Ciba Geigy and Novartis, from 2000- 2013 Chief Executive Office of Basilea

Prof. Dr. med. Andreas Gantenbein

• Expert in neurology, including electroencephalography, electroneuro-myography, sleep diagnostics and pain medicine
• From 2010 to 2012, head of the Headache and Pain Unit at the University Hospital of Zurich, from 2012 - 2021 at the rehabilitation center RehaClinic Bad Zurzach (Chief Physician of Neurology)
• Focus on clinical studies, including medication overuse headache, menstrual migraine, and CGRPantibodies
• Former president of the Swiss Headache Society with more than 100 articles in peer-reviewed journals

Arnim Pause, M.Sc., Ph.D.

• Professor of Biochemistry at McGill University's Goodman Cancer Institute and the Department of Biochemistry in Montreal, Canada (2002–present)
• Held leadership roles in R&D at Boehringer Ingelheim and the Max-Planck Institute for Biochemistry
• His research expertise spans molecular medicine, with a focus on cancer biology, virology, and metabolic diseases

H1 2025

in mCHF	H1 2025	H1 2024
Revenues	5.2	2.0
Operating Results	-1.3	-3.9
Of which non-cash effects	0.2	-3.6
Of which external research and development cost and non operating result	1.2	0.5
Cash and cash equivalents	3.5	3.5

• Double digit organic growth in revenues due to strong product growth
• Significant revenue growth due to new products from Phoenix Labs from October 1, 2025
• Several other products under evaluation as ongoing business development
• Significant investments in C-PTBE-01 in preparation for the planned Phase 3 clinicaltrial
• Significant milestone of FDA meeting achieved
• Outlook: Break even targeted in 2026 on higher revenues

Takeaways

Lead Project C-PTBE-01 (Corticorelin) with blockbuster potential	▪ High unmet medical need in the treatment of PTBE ▪ Favorable read-outs from previous clinicaltrials ▪ Type B Meeting with FDA held on 9 September 2025 ▪ Market size >1 billion USD
Cash flow from operating activities	▪ Profitable distribution business ▪ Strong growth in sales
Outlook	▪ Partnering process initiated in Q3 2025 ▪ 2026: Break even result should be achieved based on significantly higher revenues independent of partnering ▪ Preparation of pivotal study and EMA meeting

Important Notice and Disclaimer

THIS DOCUMENT DOES NOT CONSTITUTE A PROSPECTUS WITHIN THE MEANING OF SWISS FINANCIAL SERVICES ACT ("FINSA"), NOR A PROSPECTUS UNDER ANY OTHER APPLICABLE LAWS AND SHOULD NOT BE TREATED AS OFFERING MATERIALS OF ANY SORT AND IS FOR INFORMATION PURPOSES ONLY. THE INFORMATION CONTAINED HEREIN IS IN SUMMARY FORM AND MUST BE CONSIDERED IN CONJUCTION WITH AND SUBJECT TO THE PUBLICLY AVAILABLE INFORMATION OF CURATIS HOLDING AG. THIS DOCUMENT IS BEING FURNISHED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED, REDISTRIBUTED OR MADE AVAILABLE IN WHOLE OR IN PART TO ANY OTHER PERSON OR ANY P URPOSE, WITHOUT THE PRIOR WRITTEN CONSENT OF CURATIS HOLDING AG.

This document contains certain forward-looking statements. Other written materials, as well as other written and oral statements made to the public, may also contain forwardlooking statements. Forward-looking statements can be identified by words such as "potential," "expected," "will," "planned," "pipeline," "outlook," "may," "could," "would," "anticipate," "seek," or similar terms, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Curatis Holding AG, of any of the transactions described; or regarding potential future sales or earnings of the group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subjec t to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements.

This document is not an offering circular or prospectus and is being furnished to you solely for your information and may not be reproduced, redistributed or made available in whole or in part to any other person for any purpose, without the prior consent of Curatis Holding AG. This document is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy, any security nor is it a recommendation to buy or sell any security. Any decision to subscribe to any securities should only be made on the basis of an independent review by you of Curatis Holding AG publicly available information. Curatis Holding AG does not accept any liability arising from the use of, or make any representation as to the accuracy or completeness of, this document or the publicly available information on Curatis Holding AG. We provide the information in this document as of the date hereof and the information contained in this document is subject to change at any time. We do not intend, and do not assume any obligation, to update any information or forward-looking statements set out in this document as a result of new information, future events or otherwise. Curatis Holding AG shall not be responsible for, or for investigating, any matter which is the subject of any statement, representation, warranty or covenant of Curatis Holding AG contained in any agreement or document relating to a transaction, or for the execution, legality, effectiveness, adequacy, genuineness, validity, enforceability or admissibi lity in evidence thereof. This document is not for distribution, directly or indirectly in or into the United States (as defined in Regulation S under the US Securities Act of 1933, as amended ("US Securities Act")). This document is not an offer to sell securities, or the solicitation of any offer to buy securities, nor shall there be any offer of securities in any jurisdiction in which such offer or sale would be unlawful. The securities mentioned in this document have not been and will not be registered under the US Securities Act, and may not be offered or sold in the United States absent registration or exemption from registration under the US Securities Act.